|
87 Products |
| 87 Products |
|
167 Diseases |  |
16588 News |  |
| 12345678910111213...193194» |
- || abiraterone acetate / Generic mfg.
Clinical, Retrospective data, Review, Journal: The efficacy of abiraterone in metastatic hormone-sensitive prostate cancer: a stratified meta-analysis based on subgroups of low or high disease volume and reconstructed individual patient data. (Pubmed Central) - Jun 18, 2025
Future investigation should aim to drive more personalized therapies and validate these findings in real world setting. PROSPERO: ;(CRD420251028079).
- ||| luxdegalutamide (ARV-766) / Novartis
Enrollment open: An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) (clinicaltrials.gov) - Jun 18, 2025
P2, N=150, Recruiting, Sponsor: Novartis Pharmaceuticals
PROSPERO: ;(CRD420251028079). Not yet recruiting --> Recruiting
- | Nebido (testosterone undecanoate depot injection) / Grunenthal
Journal: Testosterone Treatment and Sexual Function in Men: Secondary Analysis of the T4DM (Testosterone for Diabetes) Trial. (Pubmed Central) - Jun 17, 2025
Testosterone treatment enhanced sexual desire and, to a lesser extent, erectile function, particularly in older men and those with higher waist circumference or depressive symptoms. Reduced waist circumference and depression independently improved sexual function.
- | apalutamide / Generic mfg.
Journal: Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer. (Pubmed Central) - Jun 17, 2025
This applies to patients with metastasis when they are first diagnosed and to patients who develop metastasis after their diagnosis of prostate cancer. This level of ?0.02
- | abiraterone acetate / Generic mfg.
Journal: Enhanced Cytotoxicity of 10?,9?-Abiraterone Analogues Synthesized via LED Photocatalysis. (Pubmed Central) - Jun 17, 2025
This document presents 10-CH3 transposable abiraterone analogues that can be synthesized through a series of 9 to 10 reaction steps, including an LED-induced photochemical conversion step to produce 10-CH3-flipped compounds with high yields. Subsequently, the newly synthesized 10-CH3 transposable compounds were evaluated in cytotoxicity assays, demonstrating that compounds 11d and 11f, which possess 3-acetyl and 17-pyridine (or 17-benzimidazole) moieties, exhibit enhanced cytotoxicity against DU145 and HCT116 cells.
- | Ostarine (enobosarm) / Veru Inc
Journal: A single dose of 20-mg of ostarine is detectable in hair. (Pubmed Central) - Jun 16, 2025
Subsequently, the newly synthesized 10-CH3 transposable compounds were evaluated in cytotoxicity assays, demonstrating that compounds 11d and 11f, which possess 3-acetyl and 17-pyridine (or 17-benzimidazole) moieties, exhibit enhanced cytotoxicity against DU145 and HCT116 cells. No abstract available
- | prednisone / Generic mfg., abiraterone acetate / Generic mfg., Xofigo (radium Ra-223 dichloride) / Bayer
Journal: Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study. (Pubmed Central) - Jun 16, 2025
However, after the label change, radium-223 use without???2 prior lines of systemic mCRPC therapy remained relatively common in the Netherlands and Germany, possibly because radium-223 was previously recommended as first-line treatment for frail patients, and doctors still may consider it for use in these cases. We could not assess patients' eligibility for other systemic mCRPC therapies; therefore, these findings may partly reflect radium-223 on-label use in patients with contraindications for other systemic therapies.
- | Journal: Severe Late-Onset Abiraterone-Induced Hypokalemia in a Diabetic Patient With Concomitant Adrenal Gland Incidentaloma: A Diagnostic Challenge. (Pubmed Central) - Jun 16, 2025
Physicians should consider dexamethasone over prednisone in persistent MES cases, always monitoring also for the risk of developing Cushing syndrome. Given the rising prostate cancer incidence, clinicians must remain vigilant for MES-related complications with abiraterone, including delayed-onset severe hypokalemia.
- || abiraterone acetate / Generic mfg.
Clinical, Journal: Prostate Cancer and Tea: CYP17A1 Inhibition by Phytochemicals from Tea Plant Camellia sinensis L. and Implications for Anti-androgenic Effect. (Pubmed Central) - Jun 16, 2025
A library of 92 green tea-derived phytochemicals, along with the reference inhibitor abiraterone, was docked against the CYP17A1 enzyme...Collectively, these findings suggest that EGCG inhibits CYP17A1, potentially reducing androgen biosynthesis and thereby highlighting green tea as a promising natural source for PC therapeutics. Further preclinical and translational studies are warranted to substantiate the clinical applicability of green tea phytochemicals.
- || saruparib (AZD5305) / AstraZeneca
Trial completion date, Trial primary completion date: PETRANHA: Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 16, 2025
P1/2, N=190, Recruiting, Sponsor: AstraZeneca
Further preclinical and translational studies are warranted to substantiate the clinical applicability of green tea phytochemicals. Trial completion date: Jul 2031 --> Apr 2031 | Trial primary completion date: Jul 2031 --> Apr 2031
- | bicalutamide / Generic mfg., Ostarine (enobosarm) / Veru Inc
Preclinical, Journal: A Computational and In Vitro Appraisal of Ostarine to Target Androgen Receptor in Glioma C6 Cells. (Pubmed Central) - Jun 14, 2025
The IC50 value of Ostarine demonstrated a twofold-increase in the inhibition of C6 cells as compared to Bicalutamide. Further, cell viability, cell migration and cell invasion assays indicated the potential of Ostarine as an AR antagonist that holds chemotherapeutic promise in containing the propagation of gliomas C6 cells.
- | metformin / Generic mfg., letrozole / Generic mfg., abiraterone acetate / Generic mfg.
Preclinical, Journal: Erchen Decoction ameliorates the rat model of polycystic ovary syndrome by regulating the steroid biosynthesis pathway. (Pubmed Central) - Jun 14, 2025
These interactions were further confirmed in vitro using MST and validated at the cellular level. Our results offer a scientific foundation for the therapeutic application of ECD in PCOS treatment.
- |||| Pluvicto (lutetium Lu 177 vipivotide tetraxetan) / Novartis
Enrollment open: PSMAndARPI: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC (clinicaltrials.gov) - Jun 13, 2025
P2, N=420, Recruiting, Sponsor: Novartis Pharmaceuticals
Our results offer a scientific foundation for the therapeutic application of ECD in PCOS treatment. Not yet recruiting --> Recruiting
- 177Lu-rosopatamab tetraxetan (TLX591) / Telix
A Multinational, Multicenter, Prospective, Randomized, Controlled, Open-Label, Phase 3 Study of Lutetium (177Lu) Rosopatamab Tetraxetan in Combination with Standard of Care Versus Standard of Care Alone in Patients with Prostate-Specific Membrane Antigen (Science Pavilion; Screen 18; Hall B-C (Convention Center)) - Jun 13, 2025 - Abstract #SNMMI2025SNMMI_1938;
P3
Combining the advantages of targeted radiotherapy and immunotherapy, along with proven patient selection capabilities of 68Ga-PSMA-11 PET, provides reasonable justification for further evaluation of 177Lu-rosopatamab in a large-scale trial. This study is sponsored by Telix Pharmaceuticals.
- | Xtandi (enzalutamide) / Pfizer, Astellas
Journal: Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. (Pubmed Central) - Jun 12, 2025
Patients with diabetes experienced higher rates of acute care use compared with those without diabetes among all ARSI types. Future studies should assess potential interventions in older patients with diabetes on ARSIs.
- ||| Nubeqa (darolutamide) / Bayer, Orion Corp
Trial completion date, Real-world evidence: DEAR-EXT: An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings (clinicaltrials.gov) - Jun 12, 2025
P=N/A, N=1375, Completed, Sponsor: Bayer
Future studies should assess potential interventions in older patients with diabetes on ARSIs. Trial completion date: Jun 2024 --> Oct 2024
- | HLD-0915 / Halda Therap
Journal: RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials. (Pubmed Central) - Jun 12, 2025
Trial completion date: Jun 2024 --> Oct 2024 No abstract available
- ||| abiraterone acetate / Generic mfg.
Journal, Adverse events: Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort. (Pubmed Central) - Jun 12, 2025
Our results show that HT-associated cardiovascular risk may be synergistically amplified by dyslipidemia. These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors.
- | Trial completion date, Trial primary completion date: Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation (clinicaltrials.gov) - Jun 12, 2025
P2, N=57, Recruiting, Sponsor: University of Chicago
These results suggest that risk stratification by dyslipidemia status may improve cardiovascular outcomes for prostate cancer survivors. Trial completion date: Apr 2028 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Dec 2028
- | cyproterone acetate / Generic mfg.
Journal: Approach to prolactin monitoring and hyperprolactinaemia in transgender and gender-diverse individuals undergoing gender affirming hormone therapy. (Pubmed Central) - Jun 11, 2025
Trial completion date: Apr 2028 --> Dec 2028 | Trial primary completion date: Apr 2026 --> Dec 2028 No abstract available
- | Xtandi (enzalutamide) / Pfizer, Astellas, Nubeqa (darolutamide) / Bayer, Orion Corp
Journal: Severe cutaneous adverse reactions associated with second-generation androgen receptor antagonists in prostate cancer patients. (Pubmed Central) - Jun 10, 2025
When different SGARAs were compared, SCARs were more frequently reported with apalutamide than enzalutamide and darolutamide. This indicates that patients using SGARAs, particularly apalutamide, require closer and more prolonged monitoring to facilitate the early detection and management of SCARs and to reduce the occurrence of serious outcomes.
- || Review, Journal, BRCA Biomarker, PARP Biomarker, IO biomarker: PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer. (Pubmed Central) - Jun 9, 2025
More recently, pivotal clinical trials have broadened the potential of PARPis to the other GU cancers, including urothelial carcinoma and renal cell carcinoma. In this review, we examine the biomarkers for the response to PARPis beyond mutations in BRCA1/2 and discuss the current state and future perspectives of PARPis in GU cancers.
- | ponsegromab (PF-06946860) / Pfizer, Adlumiz (anamorelin) / Helsinn, Ostarine (enobosarm) / Veru Inc
Journal: Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues. (Pubmed Central) - Jun 9, 2025
Given that the population that may be addressed in aging associated sarcopenia is vast, the safety requirement standards applied for studies may be equivalent to those of studies in type 2 diabetes mellitus. Some argued at the meeting that this would make study programs so large that from an economic standpoint only therapies that significantly impact on morbidity/mortality outcomes have a chance to be considered commercially feasible for development.
- ||| gridegalutamide (BMS-986365) / BMS
P3 data, Journal: rechARge: a randomized phase III trial of the androgen receptor ligand-directed degrader, BMS-986365, vs investigator's choice in patients with mCRPC. (Pubmed Central) - Jun 9, 2025
P3
The primary study objective is to compare the efficacy and safety of BMS-986365 versus investigator's choice of therapy. Approximately 960 patients will be enrolled.Clinical trial registration: www.clinicaltrials.gov identifier is NCT06764485.
- | Nubeqa (darolutamide) / Bayer, Orion Corp
Retrospective data, Journal: Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS. (Pubmed Central) - Jun 9, 2025
P3
Among all men with testosterone /= 20 ng/dl were not associated with poorer MFS in the first line therapy of nmCRPC with NHTs. The prognostic value of maintaining testosterone levels <20 ng/dl in patients with nmCRPC is limited and further treatment intensification is not indicated.
- | Xtandi (enzalutamide) / Pfizer, Astellas
Journal, Real-world evidence: Real-World Overall Survival Comparison of Enzalutamide and Abiraterone In First- and Second-Line Setting of Metastatic Castration-Resistant Prostate Cancer. (Pubmed Central) - Jun 8, 2025
The prognostic value of maintaining testosterone levels <20 ng/dl in patients with nmCRPC is limited and further treatment intensification is not indicated. This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS.
- ||| Olumiant (baricitinib) / Eli Lilly
Journal, Adverse events: An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System. (Pubmed Central) - Jun 6, 2025
This health insurance-registry-based study suggests that, in the real-world mCRPC setting, enzalutamide is superior to abiraterone in terms of OS. In our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID.
- | Yonsa (abiraterone acetate) / Sun Pharma
Enrollment change: Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer (clinicaltrials.gov) - Jun 6, 2025
P2, N=110, Recruiting, Sponsor: Mayo Clinic
In our study, we filtered 30 common drugs that could cause PE through the FAERS public database, which provides theoretical support for drug selection in the treatment of malignant tumors and IMID. N=57 --> 110
- | prednisone / Generic mfg., abiraterone acetate / Generic mfg.
Journal: Local therapy for oligometastatic prostate cancer. (Pubmed Central) - Jun 5, 2025
For oligoprogressive castration-resistant prostate cancer, the phase II ARTO trial demonstrated that the addition of radiotherapy targeting oligometastases to first-line abiraterone acetate and prednisone treatments improved PFS. With the global adoption of PSMA-PET, local therapy for primary tumor and metastases in oligometastatic prostate cancer is expected to play an increasingly prominent role in the future.
- || apalutamide / Generic mfg.
Clinical, Journal, Real-world evidence: Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. (Pubmed Central) - Jun 5, 2025
With the global adoption of PSMA-PET, local therapy for primary tumor and metastases in oligometastatic prostate cancer is expected to play an increasingly prominent role in the future. This real-world study revealed that apalutamide was used for the treatment after other ARSIs in >40% of patients with nmCRPC and showed limited efficacy in this context, although the effectiveness of apalutamide without prior other ARSI treatment was comparable with that reported in clinical trial results.
- ||||| abiraterone decanoate (ASP5541) / Astellas
New P2 trial: A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer (clinicaltrials.gov) - Jun 5, 2025
P2, N=218, Not yet recruiting, Sponsor: Astellas Pharma Global Development, Inc.
- | abiraterone acetate / Generic mfg.
Journal: A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer. (Pubmed Central) - Jun 5, 2025
Mechanistically, BCL6, NFIB, and SMAD3 synergistically remodel the transcriptional landscape of resistant CRPC cells, driving resistance by regulating cholesterol biosynthesis and cell cycle pathways. The findings provide critical insights into the transcriptional dysregulation underlying Abiraterone resistance and highlight potential therapeutic strategies to counteract treatment resistance in CRPC, ultimately aiming to improve patient survival and quality of life.
- | abiraterone acetate / Generic mfg., docetaxel / Generic mfg.
Journal: Drug-Induced Liver Injury Caused by Abiraterone Acetate in Patients With Prostate Cancer. (Pubmed Central) - Jun 5, 2025
Severe DILI is a potential complication of the administration of abiraterone acetate. We recommend close monitoring for liver injury during abiraterone acetate therapy, especially in the first few months.
- | docetaxel / Generic mfg.
Enrollment open: TRIPLE-SWITCH: Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (clinicaltrials.gov) - Jun 5, 2025
P3, N=830, Recruiting, Sponsor: Canadian Cancer Trials Group
We recommend close monitoring for liver injury during abiraterone acetate therapy, especially in the first few months. Not yet recruiting --> Recruiting
- | Xtandi (enzalutamide) / Pfizer, Astellas, Xofigo (radium Ra-223 dichloride) / Bayer
Journal: Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial. (Pubmed Central) - Jun 4, 2025
PEACE-3 demonstrates that combining enzalutamide with Ra223 as first-line therapy for mCRPC significantly improves rPFS. Although statistically significant at the OS interim boundary, the study will continue to the final OS analysis.
- | testosterone gel / Generic mfg.
Journal: Associations of Handgrip Strength and Testosterone With Cerebral White Matter Hyperintensity and Microstructural Injury. (Pubmed Central) - Jun 4, 2025
Our study revealed that greater HGS was linearly associated with reduced WMH volume and less white matter microstructural injury, mediated by STT. Improving muscle function may contribute to deferring white matter damage and preventing stroke and dementia, offering a feasible secondary prevention measure for CSVD.
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, Adverse events, Monotherapy: Comparative disproportionality analysis of adverse events associated with combined therapy versus monotherapy of Abiraterone and olaparib for prostate cancer: a pharmacovigilance study using the FAERS Database. (Pubmed Central) - Jun 4, 2025
We recommend patients undergo serum lipid measurement, electrocardiograms, and cardiac and vascular ultrasounds to facilitate early detection and management of potential adverse effects. Additional research is needed to confirm these results and ensure the safe application of this drug combination.
- ||||| Xtandi (enzalutamide) / Pfizer, Astellas
Enrollment change: A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces (clinicaltrials.gov) - Jun 4, 2025
P=N/A, N=2313, Completed, Sponsor: Pfizer
Additional research is needed to confirm these results and ensure the safe application of this drug combination. N=1000 --> 2313
- || apalutamide / Generic mfg.
Clinical, Journal, Real-world evidence: Apalutamide use in metastatic hormone-sensitive prostate cancer patients diagnosed by conventional and next-generation imaging. Real world data from 772 patients. (Pubmed Central) - Jun 3, 2025
N=1000 --> 2313 mHSPC patients treated with apalutamide and NGI-diagnosed exhibited superior rPFS and OS in comparison with CI-diagnosed patients.
- | abiraterone acetate / Generic mfg.
New P4 trial: Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study) (clinicaltrials.gov) - Jun 3, 2025
P4, N=29, Recruiting, Sponsor: Deventer Ziekenhuis
- | apalutamide / Generic mfg.
Journal, Real-world evidence: Liquid chromatography-tandem mass spectrometry assay for the simultaneous determination of apalutamide and its active metabolite N-desmethyl apalutamide, and its application in real-world patients with castration-resistant prostate cancer. (Pubmed Central) - Jun 3, 2025
Therapeutic drug monitoring can help evaluate the individual differences between patients taking apalutamide. A dose of 180
- | Xtandi (enzalutamide) / Pfizer, Astellas
Journal: Efficacy and Safety of Enzalutamide and Abiraterone Plus Prednisolone in Elder Castration-Resistant Prostate Cancer Patients: A Sub-Analysis From the ENABLE Study. (Pubmed Central) - Jun 3, 2025
P3
ARSIs demonstrated similar efficacy and safety in both younger and older patients. ENZ may be a more suitable option for older patients due to its higher PSA response rate.
- |||| SX-682 / Syntrix
New P1/2 trial: ASpiRE: Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - Jun 2, 2025
P1/2, N=78, Recruiting, Sponsor: Institute of Cancer Research, United Kingdom
- || Xtandi (enzalutamide) / Pfizer, Astellas, Talzenna (talazoparib) / Pfizer
Trial initiation date: TALENT: A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate (clinicaltrials.gov) - Jun 2, 2025
P2, N=126, Not yet recruiting, Sponsor: Prostate Cancer Clinical Trials Consortium
ENZ may be a more suitable option for older patients due to its higher PSA response rate. Initiation date: Apr 2025 --> Sep 2025
- || Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial completion, Trial completion date, Trial primary completion date: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jun 2, 2025
P2, N=23, Completed, Sponsor: David Oh
Initiation date: Apr 2025 --> Sep 2025 Active, not recruiting --> Completed | Trial completion date: Aug 2025 --> Mar 2025 | Trial primary completion date: Aug 2025 --> Mar 2025
- | Xtandi (enzalutamide) / Pfizer, Astellas
Biomarker, Retrospective data, Journal: Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC. (Pubmed Central) - Jun 2, 2025
The median overall survival (OS) of LTR was 78.2?months (95% CI 72.3-84.1?months) vs 27.7?months of no-LTR (95% CI 25.9-29.6?months). Several clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.
- | abiraterone acetate / Generic mfg., Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis. (Pubmed Central) - Jun 1, 2025
P3
Efficacy and safety results for olaparib plus abiraterone in the Asian subset were generally consistent with the global PROpel population supporting the combination of olaparib plus abiraterone as an important first-line treatment for consideration in Asian patients with mCRPC. Trial Registration: Clinicaltrials.gov identifier: NCT03732820.
- | abiraterone acetate / Generic mfg.
Pricing, Journal: Indication-based pricing of the pharmaceuticals in Croatia: case-study. (Pubmed Central) - Jun 1, 2025
Depending on the IBP approach chosen, drug prices can be reduced by 74% or increased by up to 280%. Drug prices can vary dramatically depending on the IBP approach chosen.
- ||| ipatasertib (RG7440) / Roche
Clinical data, P3 data, Journal: Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. (Pubmed Central) - May 30, 2025
Ipatasertib addition to abiraterone did not improve OS for men with mCRPC, regardless of PTEN status on IHC. Exploratory biomarker analyses identified additional genomic alterations of potential clinical relevance for AKT blockade in mCRPC that require further validation in prospective studies.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-na (Pubmed Central) - May 30, 2025
P1/2
Exploratory biomarker analyses identified additional genomic alterations of potential clinical relevance for AKT blockade in mCRPC that require further validation in prospective studies. Pembrolizumab plus abiraterone and prednisone demonstrated antitumor activity and acceptable safety in patients with chemotherapy-na